These findings establish LS-1-2 as a promising preclinical candidate for targeting transcriptionally addicted KRAS-mutant malignancies and provide a rationale for therapeutic targeting of the NMHC IIA/FOXO axis in hypertranscription-associated cancers. Here, KRAS is linked to cancer.